Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

Published:2023-07 Issue:7 Volume:23 Page:1062-1076
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:American Journal of Transplantation

Author:

Link-Gelles Ruth,Weber Zachary A.,Reese Sarah E.,Payne Amanda B.,Gaglani Manjusha,Adams Katherine,Kharbanda Anupam B.,Natarajan Karthik,DeSilva Malini B.,Dascomb Kristin,Irving Stephanie A.,Klein Nicola P.,Grannis Shaun J.,Ong Toan C.,Embi Peter J.,Dunne Margaret M.,Dickerson Monica,McEvoy Charlene,Arndorfer Julie,Naleway Allison L.,Goddard Kristin,Dixon Brian E.,Griggs Eric P.,Hansen John,Valvi Nimish,Najdowski Morgan,Timbol Julius,Rogerson Colin,Fireman Bruce,Fadel William F.,Patel Palak,Ray Caitlin S.,Wiegand Ryan,Ball Sarah,Tenforde Mark W.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Reference4 articles.

1. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September–November 2022;Tenforde;MMWR Morb Mortal Wkly Rep,2023

2. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

3. Effectiveness of monovalent mRNA COVID-19 vaccination in preventing COVID-19–associated invasive mechanical ventilation and death among immunocompetent adults during the Omicron variant period—IVY Network, 19 U.S. states, February 1, 2022–January 31, 2023;DeCuir;MMWR Morb Mortal Wkly Rep,2023

4. Effectiveness of COVID-19 mRNA vaccines against COVID-19–associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance—VISION Network, 10 states, December 2021–August 2022;Britton;MMWR Morb Mortal Wkly Rep,2022

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study;Journal of Infection;2024-10

2. Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study;Vaccines;2024-08-03

3. Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study;2024-05-03

4. Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States;Annals of Internal Medicine;2024-05

5. Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients;The Journal of Infectious Diseases;2024-03-21